...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Top-Line Primary Endpoint Results for Phase 3 BETonMACE Cardio Outcomes Trial were Announced September 30th ****Detailed Trial Data to be Presented at AHA Late Breaking Session Nov 16th & Company Webcast Nov 18th******

Free
Message: Comments on the AGM

Narmac, 

Interesting idea about kidney functioning to remove amyloid. There very well could be a connection between kidney disease and cognitive decline. Today's ASN Resverlogix poster reported that elevated alkaline phosphatase is associated with poorer cognitive function and increased prevalence of CKD. Furthermore, the background of the poster states:

"Increased circulating levels of ALP associate with cognitive impairment, Alzheimer’s disease and vascular dementia. Possible pathogenic mechanisms linking ALP to impaired cognition include disturbance of the blood brain barrier, impaired microcirculation, and dephosphorylation of tau."

Association of Serum Alkaline Phosphatase with CKD and Cognitive Function in Patients with Diabetes and Acute Coronary Syndrome

Share
New Message
Please login to post a reply